Kallmann syndrome in women: from genes to diagnosis and treatment

References

• de San Juan MA. Falta total de los nervios olfactorios con anosmía en un individuo en quien existía una atrofía congénita de los testículos y miembro viril. Siglo Med 1856;131:211–21
   Google Scholar
• Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidsm. Am J Mental Def 1944:48:203–36
   Google Scholar
• De Morsier G. Etudes sur les dysraphies cranio-encephaliques. I. Agenesie des lobes olfactifs (telencephaloschizis lateral) et des commissures calleuse et anterieure (telencephaloschizis median): la dysplasie olfacto-genitale. Schweizer Arch Neurol Neurochir Psych 1954:74:309–61
   Google Scholar
• Naftolin F, Harris GW, Bobrow M. Effect of purified luteinizing hormone releasing factor on normal and hypogonadotropic anosmic men. Nature 1971;232:496–7
   PubMedGoogle Scholar
• Santen RJ, Paulsen CA. Hypogonadotropic eunuchoidism. I. Clinical study of the mode of inheritance. J Clin Endocrinol Metab 1972;36:47–54
   Google Scholar
• Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971;173:1036–8
   PubMed Web of Science ®Google Scholar
• Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 1980;36:53–88
   PubMedGoogle Scholar
• Jeffcoate JL, Greenwood RH, Holland DT. Blood and urine clearance of luteinizing hormone releasing hormone in man measured by radioimmuno-assay. J Endocrinol 1974;60:305–14
   PubMedGoogle Scholar
• Gharib SD, Wierman ME, Shupnik MA, Chin WW. Molecular biology of the pituitary gonadotropins. Endocr Rev 1990;11:177–99
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Bernardi F, Monteleone P, et al. Neuropeptides, neurotransmitters, neurosteroids, and the onset of puberty. Ann NY Acad Sci 2000;900:1–9
   PubMed Web of Science ®Google Scholar
• Tobet SA, Chickering TW, King JC, et al. Expression of gamma-aminobutyric acid and gonadotropin-releasing hormone during neuronal migration through the olfactory system. Endocrinology 1996;137:5415–20
   PubMedGoogle Scholar
• Schwanzel-Fukuda M, Bick D, Pfaff DW. Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Mol Brain Res 1989;6:311–26
   PubMedGoogle Scholar
• Quinton R, Hasan W, Grant W, et al. Gonadotropin-releasing hormone immunoreactivity in the nasal epithelia of adults with Kallmann's syndrome and isolated hypogonadotropic hypogonadism and in the early midtrimester human fetus. J Clin Endocrinol Metab 1997;82:309–14
   PubMedGoogle Scholar
• Wray S, Key S, Qualls R, Fueshko SM. A subset of peripherin positive olfactory axons delineates the luteinizing hormone releasing hormone neuronal migratory pathway in developing mouse. Dev Biol 1994;166:349–54
   PubMedGoogle Scholar
• Toba Y, Pakiam J, Wray S. Voltage-gated calcium channels in the developing GnRH-1 neuronal systems. Êur J Neurosci 2005;22:79–92
   PubMedGoogle Scholar
• Silveira LF, Trarbach EB, Latronico AC. Genetics basis for GnRH-dependent pubertal disorders in humans Mol Cell Endocrinol 2010;324:30–8
   Google Scholar
• Ballabio A, Bardoni B, Carrozzo R, et al. Contiguous gene syndromes due to deletions in the distal short arm of the human X chromosome Proc Natl Acad Sci USA 1989;86:10001–5
   PubMedGoogle Scholar
• Legouis R, Hardelin JP, Levilliers J, et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991;67:423–35
   PubMed Web of Science ®Google Scholar
• Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991;353:529–36
   PubMed Web of Science ®Google Scholar
• Tsai PS, Gill JC. Mechanisms of disease: Insights into X-linked and autosomal-dominant Kallmann syndrome. Nat Clin Pract Endocrinol Metab 2006;2:160–71
   PubMedGoogle Scholar
• Trarbach EB, Silveira LG, Latronico AC. Genetic insights into human isolated gonadotropin deficiency. Pituitary 2007;10:381–91
   PubMedGoogle Scholar
• Ribeiro RS, Vieira TC, Abucham J. Reversible Kallmann syndrome: report of the first case with a KAL1 mutation and literature review. Eur J Endocrinol 2007;156:285–90
   PubMedGoogle Scholar
• Chen L, Deng CX. Roles of FGF signaling in skeletal development and human genetic diseases. Front Biosci. 2005;10:1961–76
   PubMed Web of Science ®Google Scholar
• Gill JC, Moenter SM, Tsai PS. Developmental regulation of gonadotropin-releasing hormone neurons by fibroblast growth factor signaling. Endocrinology 2004;145:3830–9
   PubMed Web of Science ®Google Scholar
• Salenave S, Chanson P, Bry H, et al. Kallmann’s syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. J Clin Endocrinol Metab 2008;93:758–63.
   PubMedGoogle Scholar
• Pitteloud N, Quinton R, Pearce S, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 2007;117:457–63
   PubMed Web of Science ®Google Scholar
• Falardeau J, Chung WC, Beenken A, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008;118:2822–31
   PubMedGoogle Scholar
• Trarbach EB, Abreu AP, Silveira LF, et al. Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency. J Clin Endocrinol Metab 2010;95:3491–6
   PubMedGoogle Scholar
• Pagon RA, Graham JM Jr, Zonana J, Yong SL. Coloboma, congenital heart disease, and choanal atresia with multiple anomalies: CHARGE association. J Pediatr 1981;99:223–7
   PubMed Web of Science ®Google Scholar
• Vissers LE, van Ravenswaaij CM, Admiraal R, et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 2004;36:955–7
   PubMed Web of Science ®Google Scholar
• Kim HG, Kurth I, Lan F, et al. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2008;83:511–9
   PubMed Web of Science ®Google Scholar
• Jongmans MC, van Ravenswaaij-Arts CM, Pitteloud N, et al. CHD7 mutations in patients initially diagnosed with Kallmann syndrome – the clinical overlap with CHARGE syndrome. Clin Genet 2009;75:65–71
   PubMed Web of Science ®Google Scholar
• Martin C, Balasubramanian R, Dwyer AA, et al. The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations. Endocr Rev 2011;32:225–46
   PubMedGoogle Scholar
• Cheng MY, Bullock CM, Li C, et al. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 2002;417:405–10
   PubMed Web of Science ®Google Scholar
• Lin DC, Bullock CM, Ehlert FJ, et al. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem 2002;277:19276–80
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Yamazaki C, Masumoto KH, et al. Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. Proc Natl Acad Sci USA 2006;103:4140–5
   PubMedGoogle Scholar
• Pitteloud N, Zhang C, Pignatelli D, et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2007;104:17447–52
   PubMed Web of Science ®Google Scholar
• Dodé C, Teixeira L, Levilliers J, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006;2:e175
   PubMed Web of Science ®Google Scholar
• Leroy C, Fouveaut C, Leclercq S, et al. Biallelic mutations in the prokineticin-2 gene in two sporadic cases of Kallmann syndrome. Eur J Hum Genet 2008;16:865–8
   PubMedGoogle Scholar
• Bullock CM, Li JD, Zhou QY. Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists. Mol Pharmacol 2004;65:582–8
   PubMedGoogle Scholar
• Bouloux PM, Hu Y, MacColl G. Recent advances in the pathogenesis of Kallmann's syndrome. Prog Brain Res 2002;141:79–83
   PubMedGoogle Scholar
• Kaplan JD, Bernstein JA, Kwan A, Hudgins L. Clues to an early diagnosis of Kallmann syndrome. Am J Med Genet A 2010;152A:2796–801
   PubMedGoogle Scholar
• Meczekalski B, Podfigurna-Stopa A, Genazzani AR. Hypoestrogenism in young women and its influence on bone mass density. Gynecol Endocrinol 2010;26:652–7
   PubMed Web of Science ®Google Scholar
• Bry-Gauillard H, Trabado S, Bouligand J, et al. Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics. Ann Endocrinol (Paris) 2010;71:158–62
   PubMedGoogle Scholar
• Pallais JC, Au M, Pitteloud N, Seminara S, et al. Kallmann syndrome. GeneReviews. 2011 Available at: http://www.ncbi.nlm.nih.gov/books/NBK1334/. Accessed December 22, 2011
   Google Scholar
• Dodé C, Hardelin JP. Kallmann syndrome. Eur J Hum Genet 2009;17:139–46
   Google Scholar
• MacColl G, Quinton R. Kallmann syndrome: bridging the gaps. J Pediatr Endocrinol Metab 2005;18:541–3
   Google Scholar
• Ravikumar B, Crowley WF Jr. Kallmann Syndrome and hypogonadotropic Hypogonadism. Concluding remarks. Front Horm Res 2010;39:168–9
   PubMedGoogle Scholar
• Sato N, Katsumata N, Kagami M, et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004;89:1079–88
   PubMedGoogle Scholar
• Doty RL. Office procedures for quantitative assessment of olfactory function. Am J Rhinol 2007;21:460–73
   PubMedGoogle Scholar
• Martin K, Santoro N, Hall J, et al. Clinical review 15: management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab 1990;71:1081A–G
   PubMed Web of Science ®Google Scholar